Engineering CAR-NK cells to express chemokine receptors such as CXCR2, CCR5, or CXCR1 has been shown to improve homing to inflamed tumor tissues, particularly in models of renal cell carcinoma and colorectal cancer [34]. This evidence concerns the gene CCR5 and neoplasm.